Immuntherapie bei Kopf-Hals-Plattenepithelkarzinomen

Ariyan CE, Brady MS, Siegelbaum RH et al (2018) Robust antitumor responses result from local chemotherapy and CTLA‑4 blockade. Cancer Immunol Res 6:189–200 Belka C, Ottinger H, Kreuzfelder E et al (1999) Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiother Oncol 50:199–204 Bensch F, Lamberts LE, Smeenk MM et al (2017) (89)Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment in patients with solid tumors. Clin Cancer Res 23:6128–6137 Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945–1952 Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‑year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28 Borcoman E, Nandikolla A, Long G et al (2018) Patterns of response and progression to immunotherapy. Am Soc Clin Oncol Educ Book 38:169–178 Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639 Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135 Brix N, Tiefenthaller A, Anders H et al (2017) Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences. Immunol Rev 280:249–279 Burnette BC, Liang H, Lee Y et al (2011) The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res 71:2488–2496 Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915–1192 Camphausen K, Moses MA, Menard C et al (2003) Radiation abscopal antitumor effect is mediated through p53. Cancer Res 63:1990–1993 The Cancer Genome Atlas Network (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576–582 Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:3541–3543 Chow LQM, Haddad R, Gupta S et al (2016) Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34:3838–3845 Cohen EEW, Soulieres D, Le Tourneau C et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393:156–167 Deng L, Liang H, Xu M et al (2014) STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41:843–852 Di Giacomo AM, Danielli R, Guidoboni M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA‑4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58:1297–1306 Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247 Ferris RL (2015) Immunology and immunotherapy of head and neck cancer. J Clin Oncol 33:3293–3304 Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867 Formenti SC, Demaria S (2012) Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys 84:879–880 Formenti SC, Rudqvist NP, Golden E et al (2018) Radiotherapy induces responses of lung cancer to CTLA‑4 blockade. Nat Med 24:1845–1851 Gandara DR, Von Pawel J, Mazieres J et al (2018) Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK study. J Thorac Oncol 13:1906–1918 George S, Motzer RJ, Hammers HJ et al (2016) Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol 2:1179–1186 Heinhuis KM, Ros W, Kok M et al (2019) Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol 30:219–235 Higashikawa K, Yagi K, Watanabe K et al (2014) 64Cu-DOTA-anti-CTLA‑4 mAb enabled PET visualization of CTLA‑4 on the T‑cell infiltrating tumor tissues. PLoS One 9:e109866 Hodi FS, Hwu WJ, Kefford R et al (2016) Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 34:1510–1517 Hodi FS, Sznol M, Kluger HM et al (2014) Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD‑1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol 32:9002–9002 Kazandjian D, Keegan P, Suzman DL et al (2017) Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials. Semin Oncol 44:3–7 Kong BY, Menzies AM, Saunders CA et al (2016) Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD‑1 therapy. Pigment Cell Melanoma Res 29:572–577 Lauber K, Dunn L (2019) Immunotherapy mythbusters in head and neck cancer: the abscopal effect and pseudoprogression. Am Soc Clin Oncol Educ Book 39:352–363 Lauber K, Ernst A, Orth M et al (2012) Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front Oncol 2:116 Lesterhuis WJ, Punt CJ, Hato SV et al (2011) Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 121:3100–3108 Lim JY, Gerber SA, Murphy SP et al (2014) Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother 63:259–271 Long GV, Weber JS, Larkin J et al (2017) Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials. JAMA Oncol 3:1511–1519 Luo R, Firat E, Gaedicke S et al (2019) Cisplatin facilitates radiation-induced abscopal effects in conjunction with PD‑1 checkpoint blockade through CXCR3/CXCL10-mediated T‑cell recruitment. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-19-1344 Mathios D, Kim JE, Mangraviti A et al (2016) Anti-PD‑1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med 8:370ra180 McCulloch HD (1908) On the analogy between spontaneous recoveries from cancer and the specific immunity induced by x ray irradiations of the lymphatic glands involved. Br Med J 2:1146–1148 Minn AJ (2015) Interferons and the immunogenic effects of cancer therapy. Trends Immunol 36:725–737 Mole RH (1953) Whole body irradiation; radiobiology or medicine? Br J Radiol 26:234–241 Ricci MS, Zong WX (2006) Chemotherapeutic approaches for targeting cell death pathways. Oncologist 11:342–357 Rizvi NA, Mazières J, Planchard D et al (2015) Activity and safety of nivolumab, an anti-PD‑1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16:257–265 Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330 Sato-Kaneko F, Yao S, Ahmadi A et al (2017) Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight 2(18):93397. https://doi.org/10.1172/jci.insight.93397 Seiwert TY, Burtness B, Mehra R et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17:956–965 Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143–e152 Shinde A, Novak J, Freeman ML et al (2019) Induction of the abscopal effect with immunotherapy and palliative radiation in metastatic head and neck squamous cell carcinoma: a case report and review of the literature. Cureus 11:e4201 Showalter A, Limaye A, Oyer JL et al (2017) Cytokines in immunogenic cell death: applications for cancer immunotherapy. Cytokine 97:123–132 Sistigu A, Yamazaki T, Vacchelli E et al (2014) Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20:1301–1309 Solinas C, Porcu M, Hlavata Z et al (2017) Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Crit Rev Oncol Hematol 120:13–21 Szturz P, Vermorken JB (2017) Immunotherapy in head and neck cancer: aiming at EXTREME precision. BMC Med 15:110 Takeshima T, Chamoto K, Wakita D et al (2010) Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res 70:2697–2706 Tran L, Allen CT, Xiao R et al (2017) Cisplatin alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma. Cancer Immunol Res 5:1141–1151 Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127 Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA‑4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375–384